Paolo Angelini
Interventional Cardiology · Houston, TXNPI 1114947645
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 406 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,234 and has fallen 81.5% since, to $413 in 2023. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.
Across 406 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Amgen$825
- Novartis$659
- Sanofi-aventis U.S. LLC$422
- Kowa Pharmaceuticals America, Inc.$414
- Boston Scientific$406
- plus $3K from 25 others
What the payments were for
- Food & beverage$7,121100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 107 | $1,411 |
| Amgen | 48 | $825 |
| Novartis | 35 | $659 |
| Sanofi-aventis U.S. LLC | 28 | $422 |
| Kowa Pharmaceuticals America, Inc. | 26 | $414 |
| Boston Scientific | 8 | $406 |
| Actelion Pharmaceuticals US, Inc. | 18 | $339 |
| E.r. Squibb & Sons, L.L.C. | 28 | $324 |
| Abbott | 8 | $264 |
| Pfizer | 9 | $227 |
| Novo Nordisk | 10 | $214 |
| Esperion Therapeutics, Inc. | 12 | $210 |
| Regeneron Healthcare Solutions, Inc. | 10 | $209 |
| Impulse Dynamics (USA) Inc. | 7 | $194 |
| Astellas Pharma US Inc | 7 | $137 |
| Akcea Therapeutics, Inc. | 4 | $116 |
| Boehringer Ingelheim | 6 | $111 |
| Merck | 7 | $108 |
| Amarin Pharma, Inc. | 4 | $86 |
| Endologix LLC | 2 | $69 |
| Heartflow, Inc. | 2 | $68 |
| Vifor Pharma, Inc. | 4 | $65 |
| Irhythm Technologies, Inc. | 3 | $49 |
| Bayer | 3 | $41 |
| Inari Medical, Inc. | 2 | $39 |
| Chiesi USA, Inc. | 2 | $29 |
| AstraZeneca | 2 | $26 |
| Avinger Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Medtronic | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,129 in reported general payments places this provider in the 40th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Juan GranadaHouston$4.1M
- John IsaacHouston$1.8M
- Sanjay KunapuliHouston$267K
- Michele SartoriHouston$266K
- Abhijeet DhobleHouston$161K
- Amir KashaniHouston$148K
- Dhaval ParekhHouston$137K
- Neal KleimanHouston$118K
- Mehran MassumiHouston$114K
- Eduardo HernandezHouston$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.